Hypofractionated radiotherapy with Tomotherapy for patients with hepatic oligometastases: retrospective analysis of two institutions

To evaluate the efficacy and toxicity for patients with hepatic oligometastases, receiving hypofractionated radiotherapy with Tomotherapy to the liver. A total of 42 patients with 54 hepatic lesions, who had been treated from 2007 to 2011 at two institutions, were retrospectively reviewed for this s...

Full description

Saved in:
Bibliographic Details
Published in:Clinical & experimental metastasis 2013-06, Vol.30 (5), p.643-650
Main Authors: Lee, Jong Hoon, Lee, Joo Hwan, Jang, Hong Seok, Lee, Hyo Chun, Lee, Jung Won, Kang, Dae Gyu, Shim, Byoung Yong, Kye, Bong-Hyeon, Kim, Hyung Jin, Cho, Hyeon-Min, Suh, Young Jin, Kim, Sung Hwan
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Biomedical and Life Sciences
Biomedicine
Cancer Research
Colorectal cancer
Dose Fractionation
Female
Hematology
Humans
Liver Neoplasms - radiotherapy
Liver Neoplasms - secondary
Male
Middle Aged
Oncology
Radiotherapy, Intensity-Modulated
Research Paper
Retrospective Studies
Surgical Oncology
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To evaluate the efficacy and toxicity for patients with hepatic oligometastases, receiving hypofractionated radiotherapy with Tomotherapy to the liver. A total of 42 patients with 54 hepatic lesions, who had been treated from 2007 to 2011 at two institutions, were retrospectively reviewed for this study. All the patients received radical resections of the primary tumor, and had been presented with one to two hepatic lesions. The radiation dose of 40–75 Gy in 10–20 fractions (median, 50 Gy in 10 fractions) was delivered for the planning target volume. At a median follow-up time of 15 months, 1- and 2-year local control (LC) rates were 59.9 and 49.0 %, respectively. The 1- and 2-year overall survival (OS) rates were 60.0 and 44.0 %, respectively. Maximal tumor diameter of
ISSN:0262-0898
1573-7276
DOI:10.1007/s10585-013-9568-7